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ABSTRACT 
The objective of the present investigation was to optimize and develop Tenofovir Disoproxil Fumarate (TDF) loaded Nanostructured Lipid 
Carriers (NLCs) with Compritol 888 ATO as solid lipid and Oleic acid as liquid lipid by modified emulsion solvent diffusion method using Central 
Composite Design (CCD). Three independent variables viz., Lipid to Drug ratio (A), Aqueous phase pH (B) and Sonication time (min) (C) were 
taken to investigate their effect on dependent variables viz., particle size (nm) (R1), PDI (R2) and % Entrapment Efficiency (%EE) (R3). 
Optimized formula of NLC was selected from the design space which was further optimized by changing the surfactants quantity. NLCs were 
evaluated for physicochemical, morphological, solid state characterization, and in-vitro dissolution in PBS pH 6.4, PBS pH 7.4 and ACSF. The 
average particle size was found to be 94.7 ± 15.70 nm with PDI of 0.380 ± 0.024 and 134.3 ± 9.71 nm with PDI of 0.358 ± 0.038 respectively for 
T4 and T5 NLC formulation. The zeta potential value of -17.0± 3.87 mV and -17.17 ± 1.05 mV and %EE of 35.5 ± 1.04 % and 34.2 ± 2.78 %. 
Overall, the above finding shows promising results in the area of developing non-invasive intranasal route as an alternative to oral route for 
brain delivery.   
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INTRODUCTION 
In 1981, Acquired Immune Deficiency Syndrome (AIDS) was 
first detected as a new disease when unusual opportunistic 
infections and rare malignancies were observed among 
young homosexual men 1, and its causative organism human 
immunodeficiency virus (HIV) was discovered in the year 
1983 2. But, till today, AIDS is a chronic and often fatal 
disease of pandemic proportions. HIV infection results in 
cell-mediated immune deficiency through progressive loss 
and dysregulation of CD4+ T lymphocytes, leading to AIDS 3. 
When HIV was initially isolated and characterized, it was 
believed to infect only CD4 lymphocyte, and the effects were 
restricted to the suppression of the immune system. 
However, in 1985, HIV was recovered from brain tissue, 
spinal cord, and peripheral nerves of the patient. This 
observation provided evidence of the role of HIV in causing 
primary infection of the brain 4. HIV directly infects and 
injure both systemic and innate, central and peripheral 
nervous systems, immune systems through infection 
respectively of T-helper lymphocytes and of microglia, 
culminating in a wide spectrum of neuropsychiatric 
disorders or neuroAIDS. NeuroAIDS is associated with 
neurocognitive disorders such as HIV-associated dementia, 
minor neurocognitive disorder, mania/psychosis, anxiety, 
depression, seizures, mental slowness, forgetfulness, poor 
concentration, discombobulation, speech problem, decrease 
in spontaneity, myelopathy, and neuropathy with 
accompanying chronic neuropathic pain and physical 
disabilities. 4, 5, 6  
Brain/CNS is a very complex system; it provides a natural 
defense against toxic or infective agents circulating in the 
blood 7. The same mechanisms that protect the brain from 
foreign substances also restrict the entry of potentially active 
therapeutic moieties 8. The CNS delivery of antiHIV drugs is 
limited by the blood–brain and blood–CSF interfaces due to a 
combination of restricted paracellular movement, powerful 
metabolic enzymes and numerous transporters including 
members of the ATP-binding cassette (ABC) and solute 
carrier (SLC) superfamilies 9. The BBB is often the rate-
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limiting factor in determining permeation of therapeutic 
drugs into the brain 10.  
Tenofovir disoproxil fumarate (TDF), a prodrug of the 
nucleotide reverse transcriptase inhibitor, tenofovir (9-
[9(R)-2-(phosphonomethoxy) propyl]adenine; PMPA). 
Tenofovir is an acyclic nucleotide analog with potent in vitro 
and in vivo antiretroviral activity. Despite its demonstrated 
antiviral potency, tenofovir has limited oral bioavailability in 
animals. Its prodrug form Tenofovir disoproxil fumarate is 
well absorbed due to the presence of disoproxil moiety. The 
oral bioavailability of tenofovir from tenofovir DF is 25%. 
Once in the circulation, tenofovir is rapidly liberated and can 
be absorbed into cells where cellular enzymes directly 
produce the active metabolite, tenofovir diphosphate. 
Tenofovir diphosphate competitively inhibits human 
immunodeficiency virus (HIV) reverse transcription and 
causes chain termination of the nascent viral cDNA. 
Tenofovir is primarily eliminated renally as unchanged drug 
with active tubular secretion by the kidney. The terminal 
half-life of tenofovir approximately 11-14 hours. There is the 
negligible transport of tenofovir across the blood-brain 
barrier 9, 11, 12, 13. 
The blood–brain barrier (BBB) prevents drugs permeability 
into the brain and limits the management of brain diseases. 
Intranasal delivery is a convenient route of drug 
administration that can bypass the BBB and lead to a direct 
delivery of the drug to the brain due to unique relationship 
between nasal cavity and cranial cavity and transported via 
the olfactory epithelium and/or via the trigeminal nerves 
directly to the CNS (Figure 1 & Figure 2). Indeed, drug 
accumulation in the brain following intranasal application of 
a drug solution, or of a drug encapsulated in specialized 
delivery systems (DDSs), has been reported in numerous 
scientific publications.14, 15, 16 Various patents are also 
granted for delivery of bupropion, folic acid, mecamylamine, 
modafinil etc to brain through intranasal route. 17, 18, 19, 20 
Colloidal drug carriers offer a number of potential 
advantages for drug delivery. Lipid nanoparticles (LNPs) 
have attracted special interest during last few decades. Solid 
lipid nanoparticles (SLNs) and nanostructured lipid carriers 
(NLCs) are two major types of Lipid-based nanoparticles. 
SLNs were developed to overcome the limitations of other 
lipidic nanocarriers, such as emulsions, liposomes, and 
polymeric nanoparticles because they have advantages like 
good release profile and targeted drug delivery with 
excellent physical stability. In the next generation of the lipid 
nanoparticle, the presence of solid cum liquid lipid in the 
NLC leads to greater drug encapsulation and loading and 
long-term colloidal stability. In SLN, it is observed that the 
drug amount soluble in the lipid melt before particle 
production is higher than in the final SLN and such higher 
drug concentration in the melt might result in immediate 
drug expulsion during the cooling process. In contrast, in 
NLC the solid matrix of the lipid nanoparticle contains a 
nano-oil section in which drug solubility is higher, thus 
increasing the total drug loading capacity. NLC exhibit a 
biphasic drug release pattern that is, an initial burst release 
of drug followed by a sustained release at a constant rate. 
The liquid lipid located in the outer layers of the 
nanoparticles forms drug-enriched casing which leads to 
burst release of the drug at the initial stage. The conception 
of NLC that is lipid matrices which are solid, but not 
crystalline is derived from the fact that crystallization 
process itself causes the expulsion of the drug. By using 
special mixtures of solid lipids and liquid lipids, the particles 
become solid after cooling but do not crystallize. NLC have 
easily stabilized with a minimum possible concentration of 
surfactants along with best results of stability, entrapment, 
and release. Sometimes, even 0.5-1% of the surfactant is 
sufficient for developing stable NLC 21, 22. 
Compretol 888 ATO is chemically Glyceryl behenate an ester 
of glycerin with behenic acid. The latter is a long-chain 
saturated fatty acid (C22) that is found in small quantities in 
normal dietary components like dairy fats, fish oil, peanut oil 
and canola oil. Compritol 888 ATO is registered in both EP 
and USP. It is generally regarded as a relative nonirritant and 
nontoxic material. Glyceryl behenate is a fat used in 
cosmetics, foods, and oral pharmaceutical formulations. In 
cosmetics, it is mainly used as a viscosity-increasing agent in 
emulsions. In pharmaceutical formulations, it is mainly used 
as a tablet and capsule lubricant, as a lipidic coating 
excipient and matrix-forming agent for the controlled release 
of water-soluble drugs. It is also used widely as an ingredient 
for the preparation of lipidic nanoparticles such as solid lipid 
nanoparticles (SLN) and nanostructured lipid carriers (NLC) 
23, 24. 
Oleic acid consists chiefly of (Z)-9-octadecenoic acid together 
with varying amounts of saturated and other unsaturated 
acids. Oleic acid is included in the FDA Inactive Ingredients 
and it is generally regarded as a relative nonirritant and 
nontoxic material. Oleic acid is a fatty acid that occurs 
naturally in various animal and vegetable fats and oils. Oleic 
acid is the most abundant fatty acid in human adipose tissue. 
It has also been used as a penetration enhancer in 
transdermal formulations, to improve the bioavailability of 
poorly water-soluble drugs in tablet formulations. Oleic acid 
has also been tested in novel drug delivery system like NLC 
25, 26.  
Compritol 888 ATO and oleic acid both are found in various 
dietary foods. Both of these are fatty acid and degraded by 
oxidation in vivo and form acetyl-CoA (coenzyme A) which is 
entry molecule of the citric acid cycle for energy production. 
So NLC formulation with these two materials will be 
biocompatible and biodegradable, stable and can be easily 
scaled up as compared to other lipid formulations. 
The present investigation is aimed to develop TDF loaded 
NLC system to have the potential of brain delivery via non-
invasive intranasal route (IN). TDF loaded NLCs were 
formulated by Modified emulsion solvent displacement 
method and optimized using Response Surface Central 
Composite Design (CCD). The TDF loaded NLCs were 
evaluated for physicochemical, morphology, in-vitro drug 
release characteristics.  
MATERIALS AND METHODS 
Materials 
TDF and Compritol ATO 888 were received as gift sample 
from Micro Labs Ltd. (Bangalore, India). Oleic acid, Pluronic 
F-68 and Tween 80 were purchased form Himedia (Mumbai, 
India). All other chemicals and reagents were of highly 
purified grade and were used without further purification.  
Preparation of NLCs 
The NLCs were prepared by modified emulsion solvent 
diffusion method. For this purpose, Oleic acid and Compritol 
888 ATO were dissolved in ethanol with heating at 60ºC, 
which acts as lipid phase. Pluronic F-68 and Tween 80 were 
dissolved in water, which acts as aqueous phase.  
Preparation of NLC involves mixing of lipid phase with the 
aqueous phase at 60ºC. Prior to mixing both the phases were 
heated upto 60ºC 27. The lipid phase was added drop-wise 
with the help of a syringe to the aqueous phase and stirred 
on a magnetic stirrer at 60ºC for 5 minutes. Sonication of the 
preparation was done in a bath sonicator at 60ºC.  After that 
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the preparation was stirred on a magnetic stirrer until the 
temperature of preparation reduced to room temperature. 
TDF loaded NLCs were formulated by adding TDF into lipid 
phase which was added to aqueous phase and stirred on a 
magnetic stirrer. The obtained TDF-NLC suspension was 
filtered through Sephadex G-25 column to separate the NLCs 
from the unentrapped drug and freeze dried the TDF loaded 
NLCs using mannitol for further characterization. 
 
Table 1: Formulation design as per CCD for the preparation of NLCs and their obtained responses 
Run 
Lipid : 
Drug 
Aqueous 
phase pH 
Sonication 
time (min) 
Particle 
size (nm) 
PDI %EE 
Zeta 
potential 
(mV) 
%drug 
loading 
1 2.5 10.02 15 334.6 0.28 38.92 -23.6 1.45 
2 2.5 7.5 15 323.4 0.21 31.2 -26.9 1.11 
3 2.5 7.5 6.59 362.7 0.23 28.2 -24 1.03 
4 2.5 7.5 15 325.4 0.22 32.2 -25.9 1.21 
5 2 6 20 311.8 0.16 21.95 -33 0.82 
6 2 9 20 289.1 0.178 26.82 -25.2 0.98 
7 3 9 20 310.2 0.21 38.89 -21.7 1.36 
8 2.5 7.5 15 321.9 0.17 30.4 -28.9 1.10 
9 2.5 7.5 15 322.3 0.16 29.8 -24.3 1.08 
10 2 9 10 303.1 0.093 27.54 -25.3 0.99 
11 2.5 7.5 15 326.2 0.21 30 -21.9 1.08 
12 1.66 7.5 15 270.2 0.14 20.23 -24.2 0.79 
13 2.5 7.5 23.41 314.7 0.31 29.5 -21.8 1.12 
14 3 6 10 335.5 0.24 27.2 -27.9 1.11 
15 2.5 4.98 15 330 0.24 20.2 -26 0.79 
16 3 9 10 371.5 0.17 36.3 -24 1.32 
17 2.5 7.5 15 325.8 0.28 31.3 -26.9 1.15 
18 3 6 20 311.4 0.33 23.42 -25.2 0.88 
19 2 6 10 351.6 0.24 22.12 -28.9 0.82 
20 3.34 7.5 15 356.7 0.38 31.5 -25.3 1.17 
 
Experimental design 
A Response Surface Central Composite Design (CCD) was 
applied to investigate the effect of formulation variables on 
dependent variables and statistically optimize the 
formulation factors 28, 29. The Lipid to Drug ratio (A), 
Aqueous phase pH (B) and Sonication time (min) (C) were 
selected as the factors and were accordingly varied. All the 
independent and dependent variables were mentioned in 
table 2. While Particle size (nm) (R1), PDI (R2) and %EE 
(R3) were selected as dependent variables/responses. 
Design-Expert software (Version 10.0.1, Stat-Ease Inc. USA) 
was employed for designing the experiment. Experimental 
design of different trial batches of NLCs and their responses 
were expressed in table 1. The optimized formulation batch 
was selected for further study. 
 
Table 2: The independent and dependent variables and their levels in CCD. 
Variables Levels Star points (α) 
Low (-1)  Medium (0) High (+1) - α + α 
Independent variables (factors) 
A - Lipid : Drug 2 2.5 3 1.66 3.34 
B - Aqueous phase pH 6 7.5 9 4.98 10.02 
C - Sonication time (min) 10 15 20 6.59 23.41 
Dependent variables (response) 
R1 - Particle size (nm) Minimize 
R2 - PDI Minimize 
R3 – %EE Maximize 
 
Optimization, data analysis, and desirability function 
The NLC formulations were optimized by employing 
Design-Expert software using response surface 
methodology. As per the suggestion by the software, the 
polynomial model was selected which gave quadratic 
equations for all the response variables. Moreover, graphs 
were also generated by the Design-Expert software. The 
significance of these factors on the variable parameters was 
assessed by analysis of variance (ANOVA, 2-way). The results 
of ANOVA studies are shown in table 3.  
After the model fitting step, the optimization was done. 
During the optimization process, the all responses were 
considered to find out the formulation having the desired 
characteristics. The desirability function combines all the 
responses into one variable to predict the optimum levels for 
the independent variables. The desirability value of 0 
represents an unacceptable value for the responses and a 
value of 1 represents the most desired value for the 
responses. In the end, the optimized formulation as 
suggested by the software was prepared and the parameters 
were compared to the expected values as given by the 
design.
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Table 3: Summary of ANOVA results for response surface CCD of particle size, PDI and %EE 
Response  Model F value P value Inference 
Particle size (nm) quadratic 6.22 0.0043 Significant 
PDI quadratic 1.33 0.0330 Significant 
%EE quadratic 37.65 <0.0001 Significant 
 
Effect of different concentrations of surfactants on the 
optimized formulation   
The effect of different concentrations of different surfactants 
were observed using Pluronic F-68 and Tween 80 alone as 
well as combination of these two (Table 4) by changing the 
surfactants quantity in the optimized formulation. Further 
best two formulations were selected based on the particle 
size nearer to 100 nm, lower PDI, higher %EE and zeta 
potential around 15 to 25 mV. 
 
Table 4: Formulation trials to see the effect of surfactants 
Trial 
Tween 
80 
(%w/w) 
Pluronic 
F68 
(%w/w) 
Tween 80+Pluronic 
F68 (1:1) (%w/w) 
Particle 
size (nm) 
PDI %EE 
Zeta 
potential 
(mV) 
T1 1.5 0 0 30.6 0.537 23.9 -6.31 
T2 1 0 0 30.4 0.54 25.7 -10.8 
T3 0.5 0 0 112.8 0.335 34.8 -13.6 
T4 0 0 1.5 75.3 0.408 36.6 -18.1 
T5 0 0 1 138.5 0.326 36.6 -24.5 
T6 0 0 0.5 220.8 0.246 38.4 -21.2 
T7 0 1.5 0 264.1 0.261 30.2 -24.3 
T8 0 1 0 360.4 0.246 31.6 -25.6 
T9 0 0.5 0 380 0.281 32.1 -20.4 
 
Characterization of TDF loaded NLC 
Particle size, PDI and zeta potential 
Particle size and PDI of NPs were determined by dynamic 
light scattering (DLS) technique due to the Brownian motion 
of the particles using Particle size analyzer (Brookhaven 
Instrument Corporation, USA) while zeta potential was 
determined by Electophoretic Light Scattering (ELS) 
technique using a Zeta sizer ZS90, (Malvern Instrument Ltd., 
UK). 
Percent drug-loaded (%DL) and percent encapsulation 
efficiency (%EE) 
Percent encapsulation efficiency was determined by 
separating the unentrapped TDF from TDF-NLCs by using 
Sephadex G-25 column which acts on the principle of size 
exclusion chromatography. The absorbance of the 
unentrapped TDF was recorded spectrophotometrically at 
260 nm   
% DL and %EE were calculated using the following formula 
                          
                    
             
 
                                   
 
                                             
                    
 
Fourier transform infrared spectroscopy (FTIR) 
The Fourier transform infrared (FT-IR) spectra of the of 
Compritol ATO 888, Oleic acid, Pluronic F-68, TDF, Tween 80 
and NLCs were recorded on FTIR spectrophotometer 
(Bruker Alpha) in the range of 4000–400 cm-1. 
Differential scanning calorimetry (DSC) 
Differential scanning calorimetric analysis was performed 
(PerkinElmer DSC 4000) to investigate the thermal and 
crystalline behaviour of Compritol ATO 888, Oleic acid, 
Pluronic F-68, TDF, Tween 80 and NLCs. A heating rate of 
10ºC/min was employed in the range of 40–450ºC. 
X-ray diffractometry (XRD) 
Crystal characteristics of Compritol ATO 888, Pluronic F-68, 
TDF and NLCs were analyzed by powder X-ray diffraction 
(XRD) on (Bruker AXS D8 Focus). Scan parameters were set 
at 5s scan speed and increament at 0.02. A diffraction 
pattern in the range of 10–80º (2θ) was used at 25ºC. 
Scanning electron microscopy (SEM) 
The shape and surface characteristics of NLCs were 
determined by SEM (Zeiss Sigma) using gold sputter 
technique. Freeze dried NLCs were dusted onto a double 
sided tape on an aluminium stub. The stubs containing the 
sample were coated with gold. Photomicrographs were 
taken at the accelerated voltage of 5 KV. 
Transmission electron microscopy (TEM) 
The morphology of NLCs was observed under transmission 
electron microscope (FEI Tecnai G2 20 S-Twin) by using 
negative staining technique. 
In vitro drug diffusion study 
In vitro drug diffusion study was carried out using the 
dialysis bag method. Formulation equivalent to 1mg TDF 
was placed inside the bag, while 100 mL diffusion medium 
(PBS, pH 7.4, pH 6.4 and ACSF at 37ºC ± 1.0ºC) was kept in 
the receptor compartment under constant stirring during 
experiment. An aliquot of 1mL was withdrawn at 
predetermined time intervals and was replaced with drug 
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free medium and analyzed using UV spectrophotometer at 
260 nm (SHIMADZU-UV). In vitro diffusion study was carried 
out for 48 h. To study the drug release mechanism, data were 
treated with various kinetic models. A diffusion stud1y for 
each formulation was carried out in triplicate. 
RESULTS AND DISCUSSION 
Statistical experimental design 
The formulations were optimized using response surface 
central composite design. The Lipid to Drug ratio, Aqueous 
phase pH and Sonication time (min) were taken as factors 
and Particle size (nm), PDI and %EE were used as dependent 
variables. From the preliminary studies, the Lipid to Drug 
ratio was selected in the range of 2:1-3:1. Aqueous phase pH 
was kept in the range 6-9. Sonication time was found to be 
satisfactory in the range 10-20 min. In this way, under the 
experimental conditions studied, it was possible to establish 
the optimized formulation as that with Lipid to Drug ratio 
2.18:1.00, Aqueous phase pH 9 and Sonication time at 20 
min. 
Influence of independent variables on the particle size 
The effect on particle size (R1) was observed to be 
significant by ANOVA and the polynomial equation was 
found as follows: 
Particle size (R1) = +510.37736 +21.62297*A -54.33643*B -
2.65273*C +17.66667*A*B -1.58000*A*C -0.19000*B*C -
19.68561*A2 +0.77470*B2 +0.16023*C2   
(Where A- Lipid to Drug ratio, B- Aqueous phase pH, C- 
Sonication time). 
From the polynomial equation, it was observed that the 
Particle size decreases with decrease in Lipid to Drug ratio. 
Whereas increase in Aqueous phase pH and Sonication time 
results in decrease in particle size. The response surface 
graph is shown in Figure 1. 
 
 
Figure 1: (a1) Response surface curves for particle size (effect of Aqueous phase pH and Lipid to Drug ratio). (a3) Response 
surface curves for particle size (effect of Sonication time and Aqueous phase pH). (a2) Response surface curves for particle size 
(effect of sonication time and lipid to drug ratio). 
 
 
 
 
 
a3 
a2 
a1 
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Influence of independent variables on PDI 
The effect on PDI (R2) was observed to be significant by 
ANOVA and the polynomial equation was found as follows: 
PDI = +0.56499 -0.012570*A -0.047301*B -0.035998*C -
0.010167*A*B +0.006250*A*C +0.001917*B*C 
+0.019008*A2 +0.002112*B2 +0.000331*C2  
   
 (Where A- Lipid to Drug ratio, B- Aqueous phase pH, C- 
Sonication time). 
The polynomial equation shows that the PDI decreases with 
decrease in Lipid to Drug ratio, whereas Aqueous phase pH 
and Sonication time have no impact on it. The response 
surface graph is shown in Figure 2. 
 
 
 
 
Figure 2:(b1) Response surface curves for PDI (effect of Aqueous phase pH and Lipid to Drug ratio). (b2) Response surface 
curves for PDI (effect of Sonication time and Lipid to drug ratio). (b3) Response surface curves for PDI (effect of Sonication time 
and Aqueous phase pH). 
b1 
b2 
b3 
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Influence of independent variables on % EE 
The effect on % Cumulative drug permeation (R3) was 
similarly observed to be significant by ANOVA and the 
polynomial equation was found as follows: 
% EE = -15.33000 +23.73662* A -1.35022*B +0.11970*C 
+2.38000*A*B -0.015000*A*C +0.097000*B*C -6.91524*A2 -
0.18775*B2 -0.026938*C2   
   
(Where A- Lipid to Drug ratio, B- Aqueous phase pH, C- 
Sonication time). 
From the equation, it is observed that % EE increases with 
increase in Lipid to Drug ratio and Aqueous phase pH. 
Whereas Sonication time don’t have any effect on %EE. The 
response surface graph is shown in Figure 3 
 
 
 
Figure 3:(c1) Response surface curves for %EE (effect of Aqueous phase pH and Lipid to Drug ratio). (c2) Response surface 
curves for %EE (effect of Sonication time and Aqueous phase pH). (c3) Response surface curves for %EE (effect of Sonication 
time and Lipid to drug ratio) 
c1 
c2 
c3 
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Formulation optimization using the desirability function 
The aim of pharmaceutical formulation optimization is 
generally to find the levels of the variable that affect the 
chosen responses and determine the levels of the variable 
from which a robust product with high-quality 
characteristics may be produced. All the measured responses 
that may affect the quality of the product were taken into 
consideration during the optimization procedure. Upon 
“trading off” different response variables, the following 
criteria were adopted Lipid to Drug ratio, Aqueous phase pH, 
Sonication time were kept in the range. The responses of 
factorial formulations suggested a Lipid to Drug ratio 
2.18:1.00, Aqueous phase pH 9 and Sonication time at 20 min 
as the optimized formulation.  
Effect of different concentrations of surfactants on the 
optimized formulation 
Effect of different concentrations of Tween 80, Pluronic F-68 
and combination of these two on particle size, zeta potential 
and %EE were presented in Table 4. From the result it was 
seen that Teen 80 containing NLCs had lesser particle size 
compared to Pluronic F-68 composite NLCs. Whereas the 
NLCs containing combined Tween 80 and Pluronic F-68 at 
ratio 1:1 showed the intermediate particle sixe compared to 
the surfactants alone.     
Characterization of NLCs 
Particle size, PDI and zeta potential 
Three individual formulations of optimized NLCs were 
formulated and characterized for size, PDI, zeta potential, 
%EE (Table 5). Particle size measurements were required to 
confirm the production of particles in nano range. Particle 
size of T4 and T5 94.7 ± 15.70 nm with PDI of 0.380 ± 0.024 
and 134.3 ± 9.71 nm with PDI of 0.358 ± 0.038 respectively 
indicated narrow size distribution with smaller size. Particle 
size is one of the major factor for intranasal delivery of drugs 
to the brain, because smaller the particle size larger the 
surface area thereby increased rate of drug absorption. At 
smaller size, higher amount of drug can be transported 
across the brain through olfactory region in nasal mucosa. 
Zeta potential is an electrical charge on the particle surface 
and acts as a factor for crossing biological membrane by the 
formulation. The zeta potential value of -17. ± 3.87 mV and -
17.17 ± 1.05 mV was found for T4 and T5 respectively with 
%EE of 35.5 ± 1.04 and 34.2 ± 2.78. 
  
Table 5: Characterization of T4 and T5 NLCs 
Trial Particle size (nm) PDI %EE Zeta potential %DL 
T4 94.7 ± 15.70 0.380 ± 0.024 35.5 ± 1.04 -17.0 ± 3.87 1.22 ± 1.12 
T5 134.3 ± 9.71 0.358 ± 0.038 34.2 ± 2.78 -17.17 ± 1.05 1.77 ± 0.89 
 
Morphological analysis 
SEM images representing surface morphology of NLCs are 
depicted in Figure. 4. NLCs were found to be spherical in 
shape with uniform distribution. SEM analysis revealed that 
the NLCs had smooth surface and did not show any 
aggregation. Morphological characteristic of the NLCs were 
analyzed using TEM (Figure. 4). It was observed that NLCs 
were spherical in shape. 
 
 
 
Figure 4: TEM image of T4 (a), T5 (b) and SEM image of T4 (c), T5 (d) 
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Fourier transform infrared spectra 
The FTIR spectrum of TDF (Figure 5) exhibited sharp peak at 
1752.29 cm-1 due to Carbonyl group stretching. The 
spectrum showed absorption band at 1622.33 cm-1 due to N-
H bending, whereas the absorption band at 3227.13 cm-1 due 
to N-H stretching. The absorption band at 1256.26 cm-1 and 
1680.37 cm-1 correspond to aromatic amine stretching and -
C=N- stretching respectively. Absorption band at 1184.39 
cm-1 confirms P=O stretching. The FTIR spectrum shows 
characteristic peaks of TDF Compritol ATO 888, Pluronic 
F68, Tween 80 and Oleic acid. In the IR spectrum of NLC (T4 
and T5), major peaks corresponding to TDF are merged, 
disappear or are buried in the peaks of Compritol 888 ATO 
indicating drug entrapment in lipid matrix. 
 
 
Figure 5: IR spectra of TDF, T4 and T5 NLCs 
 
Differential scanning calorimetry 
The DSC thermograms of TDF, Compritol ATO 888, Pluronic 
F68, Tween 80 and Oleic acid and NLCs were shown in 
Figure 6. Compritol ATO 888 thermogram showed 
endothermic peak at 78.53 ºC. Sharp melting endothermic 
peak of TDF was observed at 120.59 ˚C. The absence of 
characteristics endothermic peak of TDF in the DSC 
thermogram of NLCs might be because of formation of 
inclusion complex between hydrophobic cavities of 
Compritol ATO 888 and the drug in the NLCs. 
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Figure 6: DSC thermogram of TDF, T4 and T5 NLCs 
X-ray diffraction 
Figure 7 shows XRD spectra of Compritol ATO 888, TDF, 
Pluronic F-68 and NLCs. XRD spectra of TDF, Compritol ATO 
888 and Pluronic F68 shows some sharp peaks indicating its 
crystalline nature. From the spectra of NLCs it was observed 
that the XRD pattern of NLC also showed peaks for Compritol 
ATO 888 and Pluronic F68 indicating they were remained 
crystalline even in final NLC. The Sharp peaks of TDF were 
absent and/or showed very lower or negligible intensity in 
NLC indicating reduction in the crystallinity for TDF. It is 
known that, broadening and lowering of intensities observed 
in NLC compared to individual XRD spectra are characteristic 
of poor crystalline nature. This was because of entrapment of 
TDF within the NLC, thereby showing lower or negligible 
intensities for TDF in XRD spectra of NLCs. 
 
 
Figure 7: XRD of TDF, T4 and T5 NLCs 
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In vitro drug diffusion study 
The release profile of TDF from the NLCs followed a biphasic 
pattern characterized by initial burst release followed by a 
slow prolonged release in all PBS pH 6.4, pH 7.4 and ACSF 
(Figure 8, 9, 10). The initial burst release may be attributed 
to the release of adsorbed drug molecules on the surface of 
NLCs in the diffusion media. Drug release was found to be 
sustained by erosion of polymer matrix which might have 
offered sustained release effect. Drug release profiles were 
analysed using zero order, first order, Higuchi, Hixon Crowell 
and Korsemeyer-Peppas model. The release exponent value 
(n) from the Korsemeyer–Peppas equation was found to be 
less than 0.5 which displayed drug release by Fickian 
diffusion mechanism with best correlation coefficient in all 
three dissolution medium viz. PBS pH 6.4, PBS pH 7.4 and 
ACSF.
 
 
Figure 8: % cumulative drug release of T4, T5 and pure TDF in PBS pH 6.4 
 
Figure 9: % cumulative drug release of T4, T5 and pure TDF in PBS pH 7.4 
 
Figure 10: % cumulative drug release of T4, T5 and pure TDF in ACSF 
CONCLUSION 
In the present investigation CCD was successfully applied on 
the optimization and development of NLCs by modified 
emulsion solvent diffusion method. Design space was 
generated using CCD where three independent variables 
were taken to obtain optimized formula for NLCs with an 
aim to achieve lower size, PDI and higher %EE. Further the 
formula was again optimized by changing the surfactants 
which gave particle size of 94.7 ± 15.70 nm with PDI of 0.380 
± 0.024 and 134.3 ± 9.71 nm with PDI of 0.358 ± 0.038 
respectively for T4 and T5 NLC formulation. Solid state 
characterization (DSC, FTIR and XRD) confirmed entrapment 
of TDF into NLCs successfully. Sustained release effect of TDF 
was observed from the NLCs in PBS pH 6.4, PBS pH 7.4 and 
ACSF. The low particle size with desired zeta potential for 
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NLCs proved the favourable effect on modulation of tight 
junctions of nasal cavity, thereby proving the potentiality of 
NLCs for the brain delivery via IN route in the area of 
therapeutic applications.  
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